Amelotex, 10 mg/ml 1.5 ml 10 pcs

Pharmacotherapeutic group: nonsteroidal anti-inflammatory drugs.

ATX code: M01AC06

Pharmacological properties

Pharmacodynamics

Nonsteroidal anti-inflammatory drug, has anti-inflammatory, antipyretic, analgesic effects.

Selectively inhibits the enzymatic activity of cyclooxygenase-2. Suppresses the synthesis
of prostaglandins in the area of inflammation to a greater extent than in the gastric mucosa
or kidneys. Less often causes erosive and ulcerative lesions of the gastrointestinal tract.
It belongs to the class of oxycams; a derivative of enolic acid.

Pharmacokinetics

The binding to plasma proteins is 99%. Passes through the histohematic barriers, penetrates into
synovial fluid. Concentration in synovial fluid reaches 50% of the maximum concentration in plasma. Less than 5% of the daily dose is excreted unchanged through the intestines, only trace amounts of the drug are found unchanged in
the urine. The half-life (T
1/2) of meloxicam is 15-20 hours. Plasma clearance averages 8 ml/min. The drug clearance is decreased in elderly patients. Distribution volume is low and averages 11 l.

Hepatic or renal insufficiency of moderate severity has no significant effect on the pharmacokinetics of meloxicam.

Indications

Active ingredient

Composition

How to take, the dosage

Interaction

Special Instructions

Synopsis

Contraindications

Errotic ulcerative changes of the mucosa of the stomach or duodenum, active gastro-
gastrointestinal bleeding;

Cautious

To reduce the risk of adverse events, use the lowest
effective dose of the shortest possible course at:

Ischemic heart disease, cerebrovascular disease, congestive heart
failure, dyslipidemia/hyperlipidemia, diabetes mellitus, peri-
feric artery disease, smoking, creatinine clearance less than 60 ml/min, anamnestic
Data on the development of gastrointestinal ulcer disease, the presence of Helicobacter pylori infection, the elderly, prolonged use of non-steroidal
anti-inflammatory drugs, frequent alcohol consumption, severe somatic
diseases, concomitant therapy with the following drugs: anticoagulants (e.
warfarin), antiaggregants (e.
acetylsalicylic acid, clopidogrel), oral
glucocorticosteroids (e.
prednisolone), selective serotonin reuptake inhibitors (e.
citalopram, fluoxetine, paroxetine, sertraline).

Side effects

Digestive system disorders: nausea, vomiting, belching, abdominal pain, constipation or
diarrhea, flatulence, increased activity of “hepatic” transaminases, hyperbilirubinemia,
Stomatitis, erosive-ulcerative lesions of the gastrointestinal tract, esophagitis, gastritis,
colitis, gastrointestinal perforation, gastrointestinal bleeding
(latent or overt), hepatitis.

Nervous system disorders:dizziness, vertigo, headache, tinnitus, confusion, drowsiness, disorientation, emotional lability.

In the respiratory system: bronchospasm.

Hematopoietic organs:anemia, leukopenia, thrombocytopenia.

Cardiovascular system disorders:peripheral edema, increased arterial
pressure, “rushes” of blood to the face and upper chest, palpitations.

Urinary system disorders:edema, hypercreatininemia, increased serum urea
concentration. In rare cases – acute renal failure, interstitial nephritis, albuminuria, hematuria.

Sensory organs:conjunctivitis, visual impairment including blurred vision.

Skin disorders:Itching, skin rash, urticaria, photosensitization, bullous
rashes, erythema multiforme, toxic epidermal necrolysis.

Allergic reactions:angioneurotic edema, anaphylactoid, anaphylactic re-
reactions.

Local reactions:possible burning and pain at the injection site.

Overdose

Similarities